Related Experiment Videos
Effects of long-term anticoagulant therapy in subgroups after acute myocardial infarction
P Smith1, H Arnesen, M Abdelnoor
1Department of Cardiology, Ulleval Hospital, Oslo, Norway.
Insights
Warfarin therapy did not significantly reduce mortality or recurrent myocardial infarction (MI) in patients with prior MI or diabetes mellitus. Benefits of anticoagulant therapy may be reduced in older patients.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Research
Background:
- Secondary prevention of myocardial infarction (MI) is crucial.
- Long-term anticoagulant therapy is a common strategy.
- Individual patient responses to warfarin may vary.
Purpose of the Study:
- To evaluate the effectiveness of long-term warfarin therapy in specific patient subgroups after acute MI.
- To identify prognostic factors influencing warfarin's efficacy.
- To assess treatment response across different strata.
Main Methods:
- Post hoc analysis of the Warfarin Re-Infarction Study.
- Inclusion of 1214 patients with a mean treatment duration of 37 months.
- Univariate survival analyses and stratified evaluations using Cox regression models.
Main Results:
- Warfarin therapy did not favorably influence mortality in patients with prior MI.
- Recurrent MI was not significantly reduced in patients with prior MI or diabetes mellitus.
- A trend towards reduced benefit was observed in older patients, persisting after confounder control.
Conclusions:
- Warfarin therapy may lack a beneficial effect for secondary prophylaxis of MI in patients with prior MI or diabetes mellitus.
- The efficacy of warfarin may be attenuated in elderly individuals.
- Further research into personalized anticoagulant strategies is warranted.
Abstract:
This post hoc analysis of the Warfarin Re-Infarction Study evaluates the effect of long-term anticoagulant therapy in different subgroups after acute myocardial infarction (MI). The study population comprised 1214 patients. The mean duration of treatment was 37 months. The overall significance of prespecified prognostic factors was assessed by univariate survival analyses. Those risk factors that yielded a statistically significant result were evaluated with regard to response to treatment in a stratified manner. After stratification, heterogeneity across the strata was found to pertain to the effect of treatment with warfarin in subjects with prior MI and diabetes mellitus. Hence, mortality was not found to be influenced favorably by warfarin therapy in patients with previous MI. Likewise, recurrent MI was not significantly reduced by warfarin therapy in patients with prior MI or diabetes mellitus. Although not statistically significant, increasing age was associated with less benefit from therapy. The findings persisted also after controlling for possible confounders in a Cox regression model. Thus, our data suggest a lack of a beneficial effect by warfarin therapy in subjects with prior MI or diabetes mellitus, when the therapy is given for the sole purpose of secondary prophylaxis of MI. Furthermore, a trend toward an attenuated effect of therapy was found among the oldest patients.